The rationale for targeting the ICOS/ICOSL axis with agonists and antagonists is its capacity to trigger both anti-tumor T cell responses by Th1 and other effector T cells, as well as its protumor responses via Tregs (Solinas et al., 2020). Here, ICOS is linked to neoplasm.